<SEC-DOCUMENT>0001193125-18-210478.txt : 20180702
<SEC-HEADER>0001193125-18-210478.hdr.sgml : 20180702
<ACCEPTANCE-DATETIME>20180702080357
ACCESSION NUMBER:		0001193125-18-210478
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180630
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180702
DATE AS OF CHANGE:		20180702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262792552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		18931123

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		(770) 651-9100

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d655278d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): June&nbsp;30, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MIMEDX GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-35887</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">26-2792552</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>1775 West Oak Commons Ct, NE Marietta, GA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>30062</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(770) <FONT STYLE="white-space:nowrap">651-9100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 2, 2018, MiMedx Group, Inc. (the &#147;Company&#148;) announced the resignation of
Parker H. &#147;Pete&#148; Petit as Chief Executive Officer and Chairman of the Company&#146;s Board of Directors (the &#147;Board&#148;), effective as of June&nbsp;30, 2018. Mr.&nbsp;Petit continues to serve as a director of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also announced the resignation of William C. Taylor as President and Chief Operating Officer of the Company and as a director of the Board,
effective as of June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These resignations are based on the Board of Directors&#146; business judgement regarding the Company&#146;s
leadership and direction, and arise, in part, from information the Audit Committee has identified through its previously announced independent investigation. This investigation is ongoing and there may be other actions taken based, at least in part,
on information from the investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles R. Evans, the Company&#146;s lead director, has been appointed Chairman of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board appointed David Coles to serve as the Company&#146;s Interim Chief Executive Officer, effective as of July&nbsp;2, 2018. Mr.&nbsp;Coles, 53, is a
Managing Director with Alvarez&nbsp;&amp; Marsal (&#147;A&amp;M&#148;) where he has been employed since 1997. He has extensive experience helping better position companies for long-term success either through interim
<FONT STYLE="white-space:nowrap">C-suite</FONT> or advisory roles. Throughout his career, Mr.&nbsp;Coles has worked closely with executive teams at both public and private companies across a range of industries to drive business performance
improvement and preserve and enhance shareholder value. Mr.&nbsp;Coles has served as CRO of Walter Investment Management, Inc. from June 2017 through February 2018, and as interim CEO of Campus Crest Communities, Inc. from May 2015 through January
2016. Mr.&nbsp;Coles served as well as an adviser to M*Modal Inc. from October 2013 through August 2014, as CFO of PHH Corp from March 2011 through May 2012, as CFO of Lehman Brothers Holdings Inc. from September 2008 through February 2009, as
CFO&nbsp;&amp; CRO of Leiner Health Products Inc. from January 2001 through April 2002, and as COO of Applica, Inc. from October 2005 through May 2006. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;2,
2018, the Company issued a press release announcing the leadership changes described in Item 5.02 above. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and
is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d655278dex991.htm">MiMedx Group, Inc. Press Release, dated July&nbsp;2, 2018 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MIMEDX GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: July&nbsp;2, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alexandra O. Haden</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alexandra O. Haden</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel&nbsp;&amp; Secretary</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d655278dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g655278g0702104901101.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MIMEDX ANNOUNCES LEADERSHIP CHANGES AND CORPORATE ACTIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Pete Petit Resigns as Chairman and Chief Executive Officer</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Charles Evans Appointed Chairman of the Board</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Bill Taylor Resigns as President and Chief Operating Officer</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>David Coles Appointed Interim Chief Executive Officer</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Board and Management Take Decisive Action with Initiatives to Improve Corporate Compliance and Internal Operations</I> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marietta, Georgia, July</B><B></B><B>&nbsp;2, 2018</B> &#150; The Board of Directors of MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer
of regenerative and therapeutic biologics, today announced that Parker H. &#147;Pete&#148; Petit has resigned from his roles as the Company&#146;s Chairman of the Board and Chief Executive Officer but currently remains a director on the Board.
MiMedx also announced that William C. &#147;Bill&#148; Taylor has resigned as President and Chief Operating Officer and as a member of the MiMedx Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These resignations, which follow the recent departures of the Company&#146;s Chief Financial Officer and Corporate Controller and Treasurer, are based on the
Board of Directors&#146; business judgment regarding the Company&#146;s leadership and direction, and arise, in part, from information the Audit Committee has identified through its previously announced independent investigation. This investigation
is ongoing and there may be other actions taken based, at least in part, on information from the investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MiMedx Board of Directors has named
Charles R. Evans, previously the lead independent director, as Chairman of the Board, effective immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Evans has been a member of the
MiMedx Board of Directors since September 2012, and has over forty years of experience in the healthcare industry. He is a Fellow in the American College of Healthcare Executives, having previously served as Governor of the College from 2004 to 2007
and as Chairman Officer from 2008 to 2011. Additionally, in 2012, Mr.&nbsp;Evans attained the Board Leadership Fellow credential of the National Association of Corporate Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has also appointed David Coles to serve as MiMedx&#146;s interim Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Coles is a Managing Director with Alvarez&nbsp;&amp; Marsal, a global professional services firm that advises and provides services to companies in
areas that include corporate performance improvement, interim management, healthcare and corporate restructurings. He has extensive experience leading organizations on an interim basis and positioning companies for long-term success. Throughout his
career, Mr.&nbsp;Coles has worked closely with executive teams at both public and private companies across a range of industries to drive business performance improvement and preserve and enhance shareholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The Board is confident that now is the right time for MiMedx to transition its leadership team as we look to the future and prepare our Company for its
next chapter,&#148; said Mr.&nbsp;Evans. &#147;David brings years of valuable executive leadership and operational experience, and we are pleased to have him in this interim role at MiMedx, a global biopharmaceutical company serving clinicians and
improving patients&#146; lives around the world.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Coles commented, &#147;I am honored to join MiMedx and look forward to working with my
new colleagues as they continue to build on the Company&#146;s market expansion and growth opportunities. MiMedx will remain focused on executing its strategy to deliver operational and clinical successes that are expected to drive long-term value
creation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Edward J. Borkowski, MiMedx&#146;s Executive Vice President and interim CFO, stated, &#147;MiMedx has no outstanding debt, and currently
has sufficient liquidity to fund all of our operational needs and planned business investment activities. The Company continues to implement operational improvements, expand its product pipeline, grow its business, and remains focused on healthcare
providers and their patients. I look forward to partnering with David as we continue to execute our plan for the future.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g655278g0702104817888.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors has commenced a search to identify and evaluate internal and external candidates to
serve as permanent CEO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Update on Corporate Compliance and Operations Initiatives </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has taken a number of actions to promote accountability and strengthen oversight, and is supporting Company management in the development and
implementation of measures to improve MiMedx&#146;s accounting, corporate compliance and internal control practices. These initiatives include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As noted in the Company&#146;s June&nbsp;7, 2018, press release, the MiMedx Board of Directors established an Ethics and Compliance Committee, which is comprised of independent directors Luis A. Aguilar and Neil S.
Yeston, M.D. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company is also conducting a formal search for a permanent Chief Financial Officer and to fill the newly established executive positions of Chief Accounting Officer and Internal Auditor. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MiMedx has retained a leading, operationally focused finance and accounting consultancy firm to provide interim leadership for the Chief Accounting Officer, Corporate Controller and other financial roles.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company has begun to review Sarbanes-Oxley and other internal control policies and procedures, and has started the planning process to prepare restated prior-year financial statements. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investigation Update&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
previously announced, the Audit Committee of the Company&#146;s Board of Directors concluded that the Company&#146;s previously issued financial statements relating to each of the fiscal years ended December&nbsp;31, 2012, 2013, 2014, 2015, and
2016, each of the interim periods within such years and each of the interim periods ended March&nbsp;31, June&nbsp;30 and September&nbsp;30, 2017 should be restated. As a result, all communications and financial information with respect to the
fourth quarter of 2017 and the first quarter of 2018 should no longer be relied upon, and the Company has withdrawn all prior financial guidance issued for 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also as previously announced, the Company received a subpoena last year from the Securities and Exchange Commission (SEC). The Company continues to provide
documents in response to the subpoena. In parallel with the SEC&#146;s investigation, the U.S. Department of Justice is also reviewing these matters. MiMedx continues to cooperate with these regulatory agencies.The Company does not intend to provide
additional updates on the investigations until they are concluded or the Company determines that further disclosures are appropriate or necessary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MiMedx&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiMedx<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple
sectors of healthcare. <B>&#147;Innovations in Regenerative Medicine&#148;</B> is the framework behind the Company&#146;s mission to give physicians products and tissues to help the body heal itself. The Company processes the human placental tissue
utilizing its proprietary PURION<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal
sterilization. MiMedx has supplied over 1.3&nbsp;million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit
<U>www.mimedx.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
press release includes forward-looking statements. Additional forward-looking statements may be identified by words such as &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;will,&#148;
&#147;preliminary,&#148; and similar expressions, and are based on management&#146;s current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue
reliance on such statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g655278g0702104817888.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actual results may differ from those set forth in the forward-looking statements. For more detailed
information on the risks and uncertainties, please review the Risk Factors section of the Company&#146;s most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of
the date of this press release and the Company assumes no obligation to update any forward-looking statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert P. Borchert </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">770-651-9383</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rborchert@mimedx.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g655278g0702104817888.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g655278g0702104817888.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] .,# 2(  A$! Q$!_\0
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M.LX7PIXBEAFCTN^#E&;9"[ Y4]-IKNJ;L3.=JY]<4ZD 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g655278g0702104901101.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g655278g0702104901101.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] .,# 2(  A$! Q$!_\0
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M.LX7PIXBEAFCTN^#E&;9"[ Y4]-IKNJ;L3.=JY]<4ZD 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
